Factor VIII (FVIII) treatment has more than
50 years of use and over 175 clinical studies.1,2
![](/hcp/images/bg-experience-mobile.jpg)
Count on factor VIII (FVIII) prophylaxis to be there.
![](/hcp/images/bg-consistency-mobile.jpg)
Your patients are unique-so they
deserve an individualized treatment.
![](/hcp/images/bg-individualization-mobile.jpg)
Establishing a routine with
Factor VIII (FVIII) may
empower patients.
![](/hcp/images/bg-ownership-mobile.jpg)
Tailor FVIII Prophylaxis to Fit Their Lives
Management of hemophilia A has evolved beyond a “one-size-fits-all” approach to one that is multidimensional and aligned with each specific patient’s goals and lifestyle.1,2
Some patient characteristics that play into the individualization of FVIII prophylaxis include:
(Click icons to learn more)
GET THE MOST OUT OF THEIR INDIVIDUAL ROUTINE
The measurability of FVIII can help optimize a patient’s treatment regimen by allowing it to be tailored to the parameters of patients’ individual PK curves.1,3
Maintaining optimal factor coverage levels is important during situations with higher bleeding risk. Physical activity (≥50% factor levels), surgery (50%–80%), and trauma/high-risk surgery (>80%) all require level adjustment to reduce the risk of bleeds.3,4
![Clock icon depicting how important Factor VIII treatment routine is.](/hcp/images/icon-individual-routine.png)
PK-GUIDED PROPHYLAXIS UNIQUE TO YOUR PATIENTS
Using PK-guided prophylaxis with FVIII can help you gain deeper insight into peak and trough levels to better target bleeding patterns. Many patients may respond to a PK-guided routine because their chosen lifestyle and activities play a role in their treatment.5
But remember: this type of treatment requires strong commitment from your patients, as it means more intense monitoring, plus the flexibility to change as their lifestyle does.5
![Pulse graph icon from the pharmacokinetics (PK) tool.](/hcp/images/icon-pk-guided.png)
References:
1. Valentino LA. Considerations in individualizing prophylaxis in patients with haemophilia A. Haemophilia. 2014;20(5):607-615. 2. Petrini P, Valentino LA, Gringeri A, Re WM, Ewenstein B. Individualizing prophylaxis in hemophilia: a review. Expert Rev Hematol. 2015;8(2):237-246. 3. Iorio A, Iserman E, Blanchette V, et al. Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement. Haemophilia. 2017;23(3):e170-e179. 4. Broderick CR, Herbert RD, Latimer J, et al. Association between physical activity and risk of bleeding in children with hemophilia. JAMA. 2012;308(14):1452-1459 5. Hazendonk HC, van Moort I, Mathôt RA, et al. Setting the stage for individualized therapy in hemophilia: what role can pharmacokinetics play? Blood Rev. 2018;32(4):265-271.